These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 18981453

  • 1. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
    Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W.
    Toxicol Pathol; 2008 Dec; 36(7):905-16. PubMed ID: 18981453
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
    Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):204-13. PubMed ID: 19294680
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs.
    Mao Y, Xia Z, Zhang X, Zong Y, Zhu L, Yuan B, Lu G.
    Food Chem Toxicol; 2012 May; 50(5):1256-70. PubMed ID: 22343322
    [Abstract] [Full Text] [Related]

  • 4. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
    Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY.
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Sep; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 6. Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats.
    Coburn AM, Cappon GD, Bowman CJ, Stedman DB, Patyna S.
    Birth Defects Res B Dev Reprod Toxicol; 2012 Aug; 95(4):267-75. PubMed ID: 22499257
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
    Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, John-Baptiste A, Steidl-Nichols J, McHarg A.
    Cardiovasc Ther; 2012 Oct; 30(5):287-94. PubMed ID: 21884012
    [Abstract] [Full Text] [Related]

  • 8. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
    Brown AP, Courtney CL, Criswell KA, Holliman CL, Evering W, Jessen BA.
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1091-101. PubMed ID: 18509643
    [Abstract] [Full Text] [Related]

  • 9. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D.
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
    [Abstract] [Full Text] [Related]

  • 10. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Houk BE, Bello CL, Kang D, Amantea M.
    Clin Cancer Res; 2009 Apr 01; 15(7):2497-506. PubMed ID: 19258444
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib malate.
    Izzedine H, Buhaescu I, Rixe O, Deray G.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):357-64. PubMed ID: 17136543
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
    Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, Kang P.
    Drug Metab Dispos; 2012 Mar 01; 40(3):539-55. PubMed ID: 22180047
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.
    Hasinoff BB, Patel D, O'Hara KA.
    Mol Pharmacol; 2008 Dec 01; 74(6):1722-8. PubMed ID: 18815214
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
    George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD.
    Eur J Cancer; 2009 Jul 01; 45(11):1959-68. PubMed ID: 19282169
    [Abstract] [Full Text] [Related]

  • 15. Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.
    Haas B, Weber-Lassalle K, Frötschl R, Eckstein N.
    Regul Toxicol Pharmacol; 2016 Jun 01; 77():25-34. PubMed ID: 26924275
    [Abstract] [Full Text] [Related]

  • 16. Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.
    Fletcher AM, Bregman CL, Woicke J, Salcedo TW, Zidell RH, Janke HE, Fang H, Janusz WJ, Schulze GE, Mense MG.
    Toxicol Pathol; 2010 Feb 01; 38(2):267-79. PubMed ID: 20100840
    [Abstract] [Full Text] [Related]

  • 17. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R.
    Oncologist; 2007 Jan 01; 12(1):107-13. PubMed ID: 17227905
    [Abstract] [Full Text] [Related]

  • 18. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Christensen JG.
    Ann Oncol; 2007 Sep 01; 18 Suppl 10():x3-10. PubMed ID: 17761721
    [Abstract] [Full Text] [Related]

  • 19. In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.
    Dib E, Maia M, Lima Ade S, de Paula Fiod Costa E, de Moraes-Filho MN, Rodrigues EB, Penha FM, Coppini LP, de Barros NM, Coimbra Rde C, Magalhães Júnior O, Guerra T, Furlani Bde A, Freymuller E, Farah ME.
    Curr Eye Res; 2012 Jul 01; 37(7):567-74. PubMed ID: 22587017
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.
    J Oncol Pharm Pract; 2007 Mar 01; 13(1):5-15. PubMed ID: 17621562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.